Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

BACKGROUND: The tumor associated antigen (TAA) gp100 was one of the first identified and has been used in clinical trials to treat melanoma patients. However, the gp100 epitope peptide restricted to HLA-A*2402 has not been extensively examined clinically due to the ethnic variations. Since it is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Toshiyuki, Sato-Matsushita, Marimo, Kanamoto, Akira, Itoh, Akihiko, Oyaizu, Naoki, Inoue, Yusuke, Kawakami, Yutaka, Tahara, Hideaki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949666/
https://www.ncbi.nlm.nih.gov/pubmed/20843377
http://dx.doi.org/10.1186/1479-5876-8-84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949666/
https://www.ncbi.nlm.nih.gov/pubmed/20843377
http://dx.doi.org/10.1186/1479-5876-8-84

Ejemplares similares